Critical Medicines Lists in Japan and the European Union: Insights into Supply Resilience and Policy Priorities
Abstract
Regulatory authorities are increasingly developing lists of medicines that are at high risk of shortage to strengthen supply chain resilience. This study compares Japan's Ministry of Health, Labour and Welfare (MHLW) List of Medicines for Stable Supply with the European Medicines Agency (EMA) Union List of Critical Medicines, examining their regulatory roles, selection criteria, and composition using the WHO Anatomical Therapeutic Chemical classification. For antibacterial and antineoplastic agents, we also analyzed mechanisms of action, approval years, and inclusion on the WHO Essential Medicines List. The EMA list primarily includes medicines whose supply interruption would pose an immediate and serious threat to life or essential medical care over a limited period. This narrower scope, with fewer chronic disease medicines, such as antihypertensives and therapies for bone-related diseases and endocrine disorders, reflects strict criteria focused on life-sustaining importance amid economic security risks, including import disruptions. Conversely, the MHLW list is substantially broader. It encompasses not only life-saving medicines but also many chronic disease treatments, whose interruption would have less immediate clinical impact, as well as vitamins, minerals, and diagnostic agents. For antibacterial and antineoplastic agents, both lists include older, well-established medicines, whereas the MHLW-only group contains newer agents reflecting Japanese clinical practice. Although the broad scope of the MHLW list supports routine supply management, it is less suited to rapid prioritization during large-scale shortages driven by external factors. Clarifying risk scenarios and identifying priority medicines may enhance emergency response capacities.
Related
- Assessing coping, loneliness, resilience and partner burden in patients with skin conditions: protocol for a multicentre cross-sectional study across 23 dermatology centres in 15 European countries
- Insights from a workshop on climate-resilience in health systems in Japan and Germany: strategies to counteract social isolation and heat health risks for older adults
- Comorbidity Burden and Clinical Management Challenges in Severe Asthma: Insights from a Pan-European SHARP Study
- Consensus Guidance for Beta‐Lactam Antibiotic Dose Individualization in Acutely Ill Patients: Endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiology and Infectious Diseases PK/PD of Anti‐Infectives Study Group, Infectious Diseases Society of America, International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Society of Critical Care Medicine, and the Society of Infectious Diseases Pharmacists
- Next-Generation Sequencing in Practical Wildlife Disease Investigation: Metagenomic Insights into European Bison and Gazelle Mortality and Morbidity Events.
BibTeX
@article{izutsu2026critical,
title = {{Critical Medicines Lists in Japan and the European Union: Insights into Supply Resilience and Policy Priorities}},
author = {Ken-ichi Izutsu and Shoto Sasaki and Rin Kondo and Karen Namiki and Hideaki Uzawa and Hiroaki Mamiya},
journal = {Biological and Pharmaceutical Bulletin},
year = {2026},
month = sep,
doi = {10.1248/bpb.b26-00220},
url = {https://www.jstage.jst.go.jp/article/bpb/49/9/49_b26-00220/_article},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Critical Medicines Lists in Japan and the European Union: Insights into Supply Resilience and Policy Priorities
AU - Ken-ichi Izutsu
AU - Shoto Sasaki
AU - Rin Kondo
AU - Karen Namiki
AU - Hideaki Uzawa
AU - Hiroaki Mamiya
PY - 2026
DA - 2026/09/10
JO - Biological and Pharmaceutical Bulletin
DO - 10.1248/bpb.b26-00220
UR - https://www.jstage.jst.go.jp/article/bpb/49/9/49_b26-00220/_article
AB - Regulatory authorities are increasingly developing lists of medicines that are at high risk of shortage to strengthen supply chain resilience. This study compares Japan's Ministry of Health, Labour and Welfare (MHLW) List of Medicines for Stable Supply with the European Medicines Agency (EMA) Union List of Critical Medicines, examining their regulatory roles, selection criteria, and composition using the WHO Anatomical Therapeutic Chemical classification. For antibacterial and antineoplastic agents, we also analyzed mechanisms of action, approval years, and inclusion on the WHO Essential Medicines List. The EMA list primarily includes medicines whose supply interruption would pose an immediate and serious threat to life or essential medical care over a limited period. This narrower scope, with fewer chronic disease medicines, such as antihypertensives and therapies for bone-related diseases and endocrine disorders, reflects strict criteria focused on life-sustaining importance amid economic security risks, including import disruptions. Conversely, the MHLW list is substantially broader. It encompasses not only life-saving medicines but also many chronic disease treatments, whose interruption would have less immediate clinical impact, as well as vitamins, minerals, and diagnostic agents. For antibacterial and antineoplastic agents, both lists include older, well-established medicines, whereas the MHLW-only group contains newer agents reflecting Japanese clinical practice. Although the broad scope of the MHLW list supports routine supply management, it is less suited to rapid prioritization during large-scale shortages driven by external factors. Clarifying risk scenarios and identifying priority medicines may enhance emergency response capacities.
SN - 1347-5215
SN - 0918-6158
ER -